Sonnet BioTherapeutics Holdings Operating Income 2006-2021 | SONN

Sonnet BioTherapeutics Holdings operating income from 2006 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Sonnet BioTherapeutics Holdings Annual Operating Income
(Millions of US $)
2020 $-24
2019 $-16
2019 $-5
2018 $-5
2017 $-5
2016 $-3
2015 $-5
2014 $-6
2013 $-5
2012 $-3
2012 $-7
2011 $-1
2011 $-2
2010 $-0
2009 $-0
2008 $-0
2007 $0
2006 $-0
2005 $-0
Sonnet BioTherapeutics Holdings Quarterly Operating Income
(Millions of US $)
2021-06-30 $-6
2021-03-31 $-6
2020-12-31 $-6
2020-09-30 $-7
2020-06-30 $-12
2020-03-31 $-3
2019-12-31
2019-09-30 $10
2019-06-30 $-1
2019-03-31 $-2
2018-12-31
2018-09-30 $10
2018-06-30 $-0
2018-03-31 $-2
2017-12-31
2017-09-30 $11
2017-06-30 $-1
2017-03-31 $-1
2016-12-31
2016-09-30 $11
2016-06-30 $-0
2016-03-31 $-1
2015-12-31
2015-09-30 $9
2015-06-30 $-2
2015-03-31 $-2
2014-12-31
2014-09-30 $9
2014-06-30 $-1
2014-03-31 $-2
2013-12-31
2013-09-30 $-1
2013-06-30 $-1
2013-03-31 $-1
2012-12-31
2012-09-30 $-1
2012-06-30 $-1
2012-03-31 $-0
2011-12-31
2011-09-30 $-0
2011-06-30 $-0
2011-03-31 $0
2010-12-31 $-0
2010-09-30 $-0
2010-06-30 $-0
2010-03-31 $-0
2009-12-31 $-0
2009-09-30 $-0
2009-06-30 $-0
2009-03-31 $-0
2008-12-31 $-0
2008-09-30 $-0
2008-06-30 $-0
2008-03-31 $-0
2007-12-31 $-0
2007-09-30 $0
2007-06-30 $-0
2007-03-31 $-0
2006-12-31 $-0
2006-09-30 $-0
2006-06-30 $-0
2006-03-31 $-0
2005-12-31 $-0
2005-09-30 $-0
2005-06-30 $-0
2005-03-31 $-0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.015B $0.041B
Sonnet BioTherapeutics Holdings Inc. is an oncology-focused biotechnology company with a proprietary platform for biologic drugs of single or bispecific action. Sonnet BioTherapeutics Holdings Inc., formerly known as Chanticleer Holdings Inc., is based in PRINCETON, N.J.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71